(A) (Left) The cartoon depicts E1A and relevant functional domains of p300 (see text for details). (Right) 1.9 pmol of p300 were incubated with no E1A (lanes 1, 2, and 6), E1AϪ13S (lane 3), GST-E1A-13S (lane 4), or GST-E1A-12S (lane 5) prior to the addition of histone H3 and H4 (lanes 2-6). Reaction products were separated by SDS-10%-20% gradient PAGE and analyzed by phosphorimager. % of activity remaining and % inhibition of acetylation were calculated by determining the radioactivity in individual histone bands and using the values of histone H3 and H4 acetylation in lanes 2 or 6 as 100% (for % activity remaining) and 0% (for % inhibition of acetylation), respectively. GST alone or GST fusion of a nonrelated protein had no effect on the assay system. Data from two separate experiments (lanes 1-4, and lanes 5 and 6) are presented. (B) The mode of action of E1A. Acetylation assays were similar to that of Figure 1A . Lane 1 represents uninhibited p300-HAT activity. In lane 2, p300 was incubated with E1A-13S for 10 min prior to the addition of histones. In lane 3, histones and E1A were added simultaneously to p300, and reaction was continued. In lane 4, E1A-13S was added 10 min after the acetylation reaction with histones and p300. (C and D) Inhibition of p300-mediated acetylation of histone H4 (C) and H3 (D) by E1A. 1.9 pmol (80 nM) of p300 was incubated in the presence or absence of increasing amounts of GST-E1A-13S for 5 min before the addition of 50 pmol (2 M) of purified histone H4 (C) or H3 (D). Reaction products were separated by SDS-PAGE and analyzed by phosphorimager. The radioactivity in individual histone band was determined and % activity remaining calculated for each assay point using the value of p300-mediated acetylation of histone H4 (C) or H3 (D) in the absence of E1A as 100%. Purified GST fusions of wild-type E1A (construct 1) or the progressive N-terminal deletion mutants of E1A (constructs 2-6) were incubated with p300 prior to the separate addition of either purified histone H4 or H3. After incubation, products were subjected to SDS-10%-20% PAGE followed by phosphorimager analysis. % inhibition (right panels) was calculated as described in Figure 1 , using the value of uninhibited acetylation reaction as 0%. Data from two separate experiments are presented. (B) Analysis of the C-terminal deletion mutants of E1A. The HAT inhibitory activity of the GST fusion of the C-terminal deletion mutants was determined essentially as described in Figure 2A , except that the GST fusion of the C-terminal deletion mutants of E1A was used.
of PCAF in cells could counteract the mitogenic activity et al., 1996). Preincubation of either purified wild-type E1A-13S (lane 3), GST-E1A-13S (lane 4), or GST-E1A-of E1A . However, since the HAT activity of PCAF is not required for all p300/CBP-dependent 12S (lane 5) with p300 resulted in dramatic (70%-90%) inhibition of histone H4 and H3 acetylation ( Figure 1A , transcription, PCAF displacement alone may not be sufficient to fully account for the repressive effects of E1A bottom panels). Together, these results suggest that E1A can not only bind p300 but also can inhibit its intrin-(Puri et al., 1997; Korzus et al., 1998). Furthermore, the PCAF-dependent transcription is also inhibited by E1A sic HAT activity. An order of addition experiment was carried out to demonstrate that E1A must be present at (Puri et al., 1997). These results demonstrate the complex nature of E1A action and suggest additional mechathe beginning of the reaction. A standard uninhibited p300-mediated histone acetylation reaction is shown in nisms other than PCAF displacement for the inhibitory activity of E1A. The proximity of the E1A-binding site to Figure 1B , lane 1. Incubation of p300 with E1A prior to the addition of histones, as expected, led to severe the HAT domain of p300/CBP and the ability of E1A to interfere with both p300/CBP and PCAF function led inhibition of histone acetylation (lane 2). Interestingly, simultaneous addition of a 1:1 molar ratio of E1A and us to consider the additional possibility that E1A may modulate the enzymatic activity of both p300/CBP and histones to p300 also resulted in the inhibition of the HAT activity (compare lane 2 with lane 3), indicating the PCAF. Here, we provide biochemical, mutational, and functional data demonstrating E1A is a potent inhibitor rapid nature of E1A action. However, if E1A was added 10 min after the standard acetylation reaction, little or no of the acetyltransferase activity of p300/CBP, free PCAF, as well as the PCAF complex in vitro and that this inhibiinhibition was observed (lane 4, and Figure 1B, Figure 1C , of E1A on the p300-HAT activity are presented in Figure  1 . In agreement with previous studies, p300 acetylates the addition of increasing amounts of E1A progressively inhibited p300-mediated histone H4 acetylation. Higher histones H4 and H3 ( Figure 1A , lanes 2 and 6) (Ogryzko E1A concentration was, however, necessary for the inhibition of histone H3 acetylation ( Figure 1D ). Under these experimental conditions, the IC 50 (inhibitory concentration for 50% reduction of the HAT activity) values of 1.6 M for histone H4 and 8.4 M for histone H3, respectively, were obtained. While the biological significance of this preference is unclear, we conclude that the nature of the substrate as well as the abundance of E1A can affect the outcome of the reaction.
The Carboxyl Terminus of E1A Is the HAT Inhibitory Domain
Deletion mutants of E1A-13S protein were generated to map the putative inhibitory domain. Since the E1A-binding site and the HAT domain of p300/CBP are adjacent but do not overlap, we presumed the acetylase inhibitory function in E1A would reside in a region distinct from the p300/CBP interaction domain. Three regions of E1A termed CR1, CR2, and CR3 are conserved and apoptosis (Lill et al., 1997). These observations led These results indicate that the first 76 amino acids of us to ask whether E1A also inhibits p300-mediated p53 E1A, known to be involved in p300 binding, are not acetylation. To examine this possibility, purified p300 required for the inhibition of the p300-HAT activity and and p53 were incubated in the presence or absence suggest that the inhibitory activity may reside in other of E1A, and reaction products were analyzed. As with E1A domains. Additional deletion mutants were, therehistones, p300-mediated p53 acetylation ( Figure 3A , fore, generated and used in inhibition assays to map lane 1) was severely inhibited by the E1A protein (lane the HAT inhibitory domain. While the first N-terminal 120 2). In contrast, the E1A-13S-N185 mutant (Figure 2A ) amino acids were dispensable (construct 4), deletion of lacking the HAT inhibitory domain failed to inhibit p53 the CR2 and CR3 regions of E1A progressively elimiacetylation (lane 3). Interestingly, we also observed parnated inhibition (constructs 5 and 6, respectively, and tial acetylation of E1A. The biological significance of right panel).
this acetylation is not clear at present, although it does A series of complementary carboxy-terminal deletions indicate that the acetylation function is not completely of E1A were also generated and tested for their ability disabled (see Figure 5) . Nonetheless, we can conclude to inhibit the p300-HAT activity ( Figure 2B ). As expected, both histone and nonhistone substrates are subject to while the deletion of the carboxy-terminal 97 amino E1A inhibition. acids had minimal effect (constructs 2 and 3, and right panel), inhibitory activity was predominantly eliminated E1A Directly Binds to the Minimal HAT Domain when the CR3, CR2, and the carboxyl terminus were of p300 and Inhibits Its Activity deleted (constructs 4 and 5, and right panel). Consistent
The cysteine-histidine-rich region 3 (CH3) of p300/CBP with the results of Figure 2A , the N-terminal 76 amino (amino acids 1763-1811 of p300) is adjacent to the HAT acids of E1A had little or no effect on the HAT activity domain and was previously shown to bind to the N (construct 6, and right panel Figure 4B, lane 3, when a p300 that hypothesis, inhibition studies on PCAF-mediated acetylation reactions were carried out. Mononucleoderivative containing the HAT and CH3 domains (amino acids 1062-1963) was incubated with GST-E1A-13S, somes (MNS) as well as free histone H4 were incubated separately with purified PCAF in the presence or absubstantial binding was observed. This binding, as expected, was reduced (60%) but not completely elimisence of E1A derivatives and products analyzed. As shown in Figure 5A , lanes 1 and 4, PCAF acetylated nated when E1A-13S-N76 was used as the GST affinity matrix (lane 4). No binding, however, was observed with both free and nucleosomal histones (autoradiograph, two left panels). As with free histones, acetylation of the GST matrix alone (lane 2). As predicted, we also observed the binding of radiolabeled p300 minimal HAT MNS by PCAF was also severely inhibited (70%) by the wild-type E1A protein (lanes 2 and 5). As expected, the domain devoid of CH3 (amino acids 1195-1762), with either GST-E1A-13S or GST-E1A-13S-N76 (lanes 7 and E1A-13S-N185 mutant (Figure 2A ) had no effect (lanes 3 and 6). Interestingly, we also observed the acetylation 8, respectively). 4) and nal 230 amino acids had little or no effect on binding ( Figure 6C, lanes 2, 4, 6, and 14) , the deletion of the first MNS (lanes 9-11). As expected, the E1A mutant lacking the HAT inhibitory domain failed to inhibit the activity 521 amino acids (including EID1) of PCAF revealed a second binding site, termed EID2 ( Figures 6A and 6C , of the complex on either free histone H4 (lanes 5-7) or MNS (lanes 12-14) . These results show that like p300, lanes 8, 10, and 12). Interestingly, the EID2 (amino acids 521-601) encompasses the PCAF-HAT domain. Taken the HAT activity of either the purified PCAF protein or the PCAF complex, both of which are free of p300 activity, is together, these results suggest E1A, as with p300, may disrupt the PCAF complex as well as inhibit its HAT also inhibited by E1A and suggest these two proteins may physically interact. activity. To address this possibility, [ To demonstrate that the HAT inhibitory activity of E1A action domain to the same region where p300/CBP also bind (PID, Figure 6A) . is important for its ability to inhibit p300-dependent transactivation in vivo, cell-based assays were perWe also mapped the E1A interaction domains in PCAF ( Figure 6C ). For this purpose, in vitro labeled PCAF and formed. Eukaryotic expression constructs of the same carboxyl-terminal ( Figure 7A ) and amino-terminal (Figits deletion mutants were incubated with GST-E1A and bound proteins analyzed. As with p300/CBP, two bindure 7B) deletion mutants of E1A used in the in vitro inhibition assays (Figure 2) were, therefore, generated ing sites were found. The first is at the N terminus of 5 and 6) . Surprisingly, the -C79 mutant that still retains the previously shown emphasize multiple functions of E1A, but also reveal the different contribution and dependency of the p300/CBP p300/CBP interaction domain failed to repress the reporter gene activity (lane 7). These results show that the and PCAF complexes to activation by different classes of transcription factors. HAT inhibitory domain is necessary for E1A inhibition of the p300-dependent Stat1␣ function in vivo.
Additional N-terminal deletion mutants of E1A were Discussion utilized to determine the relative contribution of the N terminus and the HAT inhibitory domain in the E1A-This work provides biochemical and functional evidence that the E1A oncoprotein can inhibit the HAT activity of mediated inhibition. As shown in Figure 7B , lanes 3 and 4, deletion of the first 76 amino acids partially eliminated both p300/CBP and PCAF and suggests that modulation of acetylation may constitute a novel mechanism of traninhibition. However, additional deletion of CR2 and CR3 completely eliminated the inhibition (lanes 6 and 7) . In scriptional control. Although E1A blocks both histone H4 and H3 acetylation, it displays a pronounced prefercontrast, in a parallel series of experiments, we found the N-terminal region of E1A to be sufficient to block ence for histone H4 inhibition. While the basis for this selective inhibition is not clear, biochemical and genetic nuclear hormone receptor function (data not shown). studies suggest the acetylation of specific lysine resior overlapping region within p300/CBP. In the second step, the C terminus of E1A acts to directly inhibit the dues of the histone H4 tail plays an important role in transcription, which might also underlie E1A's preferen-HAT function. Therefore, the tethering of E1A via its N terminus to p300/CBP or PCAF (step 1) enables the tial activity (Rundlett et al., 1998) . Additionally, this inhibition is not restricted to histones, as potent effects are C-terminal CR2 and CR3 regions to modulate the HAT function (step 2). Additionally, the binding of E1A to the also seen with a block of p53 acetylation. The physiological relevance of this inhibition is strengthened by the N terminus of PCAF may strengthen the transcriptional block, since p300/CBP also binds to the N terminus of observation that E1A blocks the activity of the PCAF complex. These results in conjunction with the demon-PCAF. We speculate that, in aggregate, these interactions cooperate to manifest the complete repressive strated block of p300-dependent Stat1␣ signaling suggest a potentially global role for E1A and acetylase inhiactivity of E1A in vivo. In addition to associating with each other, p300/CBP bition in chromatin modification and transcriptional regulation.
and PCAF associate with numerous other costimulatory proteins, which presumably results in the generation of A combination of mapping and functional studies suggests that E1A inhibition may occur in a two-step proa megacoactivation complex (Glass et al., 1997; Ogryzko et al., 1998) . On the assumption that these megacomcess involving multiple independent but mutually cooperative interactions. First, as shown previously for p300 plexes act cooperatively, then disruption of the complex formation might seem adequate to account for the inhiband in Figure 6 for PCAF, the N-terminal 76 amino acids of E1A mediate direct binding to either p300/CBP or itory effects of E1A. However, recent data suggest that PCAF may act independently of p300/CBP, and thus PCAF. While this region does not inhibit the HAT activity, it appears to be essential for disruption of the p300/ simple disruption of a p300 complex may not be sufficient to ensure inhibition of all p300/CBP and PCAF CBP-PCAF complex in vivo. This disruption is a consequence of the fact that E1A and PCAF bind to the same target gene activation. Even under such a scenario, the 
scription (Barlev et al., 1998).
Transfection Assays CV1 cells were transiently transfected in triplicates in 48-well plates Experimental Procedures with 2 ϫ 10 4 cells/well using lipofection/DOTAP method (BoehringerMannheim). The following amounts of DNAs were used per well: Plasmids and Proteins Gal4-p300 derivatives were generated by cloning the appropriate 3Xly6E-Luciferase reporter (20 ng), CMX-␤-galactosidase internal control (60 ng), CMV-Stat1␣ (10 ng), and various CMX-E1A expres-PCR-amplified p300 fragments into CMX-Gal4N vector (Chakravarti et al., 1996) . PCR-amplified PCAF fragments were cloned into sion vectors (1.5 ng for Figure 7A and 6 ng for Figure 7B , respectively) as described in the figure. Five hours after transfection, cells were CAN(N) vector. In vitro radiolabeled p300 and PCAF proteins were synthesized using appropriate plasmids in TNT-coupled reticulocyte treated with IFN␥ for 8 hr. Lysate from each sample was prepared, and luciferase activity was determined and normalized by the level lysates system (Promega). For the purification of FLAG-tagged p300 and its derivative, SF9 cells were grown to 80% confluence in five of ␤-galactosidase. Relative normalized reporter activity was plotted using the value of the luciferase activity of extracts prepared from 150 mm tissue culture dishes, infected either with recombinant p300 baculovirus or p300 amino acids 1195-1761 baculovirus and grown cells transfected without any E1A expression vector as 100%. (IFN␥,
